InflaRx N.V. (IFRX) earnings
IFRX earnings moved a median of -2.29% by the close. Quarterly and annual IFRX reports and results, each read against the price at its own news timestamp. Back to the IFRX overview →
14 measured IFRX earnings events.
Where these IFRX earnings landedvs 14 measured IFRX earnings reactions
| Middle 50% of IFRX earnings reactions | -2.76% to +2.57% |
|---|---|
| Median reaction (to close) | -2.29% |
| Measured reactions | 14 |
Point-in-time · zero look-ahead
Half of the 14 IFRX earnings events with a measured close landed between -2.76% and +2.57%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Press release | -0.28% | -2.83% | |
| InflaRx to Report Second Quarter 2026 Results on August 6, 2026 | Press release | +2.38% | +2.38% | |
| InflaRx to Report First Quarter 2026 Results on May 7, 2026 | Press release | -0.73% | +2.94% | |
| InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -1.25% | +1.89% | |
| InflaRx to Report Second Quarter 2025 Results on August 7, 2025 | Press release | +0.00% | +2.71% | |
| InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -1.86% | -7.45% | |
| InflaRx to Report First Quarter 2025 Results on May 7, 2025 | Press release | -1.37% | +17.24% | |
| InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | +2.63% | |
| InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference | Press release | +0.00% | -2.52% | |
| InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | -2.90% | |
| InflaRx to Report Second Quarter 2024 Results on August 8, 2024 | Press release | +0.00% | -2.56% | |
| InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +4.88% | -2.44% | |
| InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 | Press release | -0.71% | -2.14% | |
| InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -3.51% | -5.26% |
Keep exploring
More IFRX: analyst actions → · SEC filings → · IFRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.